Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

clinical trial

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT01630590

P6099clinical trial phasephase II clinical trialQ42824440
P17countryUnited States of AmericaQ30
P582end time2020-01-08
P921main subjectmetastatic prostate carcinomaQ55779807
P1132number of participants60
P6153research siteThe University of Texas MD Anderson Cancer CenterQ1525831
P580start time2014-01-08
P8363study typeinterventional studyQ78089383
P1476titleAn Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Search more.